ArticleJournal of veterinary science2025
Evaluation of different PK/PD ratios of three enrofloxacin preparations on the clinical response of pneumonic calves.
Article in Journal of veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pharmacokinetic Profiles of Enrofloxacin and Its Metabolite Ciprofloxacin Administered by Different Doses in Calves.Journal of veterinary pharmacology and therapeutics · 2026Article
- Effect of flunixin meglumine on the pharmacokinetics of enrofloxacin and marbofloxacin in preweaning calves.The Veterinary record · 2026Article
- The Influence of Age on the Pharmacokinetics of Enrofloxacin and Ciprofloxacin in Calves.Veterinary sciences · 2026Article
- Pharmacokinetic evaluation of a long-acting, tasteless oral formulation of enrofloxacin in dogs.Open veterinary journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
importanceEnrofloxacin preparations are available for administration daily or every 3 days. This study presents clinical evidence to define which preparation is adequate to treat clinical cases of bovine respiratory disease (BRD) in calves.
objectiveTo correlate the pharmacokinetics/pharmacodynamics (PK/PD) ratios of three pharmaceutical preparations of enrofloxacin with their clinical efficacy in treating BRD.
methodsThe PK/PD ratios of three enrofloxacin preparations were determined in healthy calves. Then, 48 BRD-affected calves initially treated IV with 2.2 mg/kg of flunixin-meglumine, were randomly assigned to treatment with: enrofloxacin dihydrate-hydrochloride (enro-C) 10% water suspension daily (10 mg/kg subcutaneous for three to six days); enro-C with alginate (enro-C/Al), and reference enrofloxacin (enro-R), both intended for treatment every 72-h in two occasions (10 mg/kg).
resultsThe highest maximum plasma concentration (Cmax)/minimum inhibitory concentration (MIC) ratio was obtained with enro-C and the highest area under the curve (AUC) CONCLUSIONS AND RELEVANCE: If the priority in calves affected by BRD is to speed up their recovery, and despite the more significant amount enro-C injected, using of lower doses of enrofloxacin as in the long-acting preparations is unsustainable. This study demonstrates that the clinical efficacy of enrofloxacin in cattle is optimally linked to Cmax/MIC rather than to AUC/MIC, which occurs better when injecting enro-C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.